Avenue Therapeutics Inc

NASDAQ:ATXI   3:59:50 PM EDT
1.83
+0.04 (+2.24%)
Regulatory, Other Pre-Announcement

Fortress Biotech - Avenue Therapeutics Intends To Continue To Pursue Approval For IV Tramadol

Published: 07/15/2021 10:53 GMT
Avenue Therapeutics Inc (ATXI) - Fortress Biotech - Avenue Therapeutics Intends to Continue to Pursue Approval for Iv Tramadol & Has Type a Meeting Scheduled With FDA for Late July.
Fortress Biotech - Avenue Currently Expects to Submit a Formal Dispute Resolution Request With FDA Following Meeting.
Fortress Biotech - Avenue is Targeting a Submission of Fdrr for Iv Tramadol in the Third Quarter of 2021.